NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) will present three digital posters at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28-30, 2026.

The presentations cover obicetrapib kidney outcomes from BROADWAY, a pooled Phase III safety analysis, and LDL particle–CVD risk relationships, with presenters from company leadership and collaborators.

News Market Reaction – NAMS

+3.70%

1 alert

+3.70% News Effect

On the day this news was published, NAMS gained 3.70%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ACC.26 dates: March 28–30, 2026 First presentation time: 3:30–3:37 PM CDT Second presentation time: 10:18–10:25 AM CDT +2 more

5 metrics

ACC.26 dates March 28–30, 2026 American College of Cardiology Annual Scientific Session schedule

First presentation time 3:30–3:37 PM CDT BROADWAY kidney function poster on March 28, 2026

Second presentation time 10:18–10:25 AM CDT Integrated pooled Phase III safety analysis on March 29, 2026

Third presentation time 11:00–11:07 AM CDT Cardiovascular events and LDL particle analysis on March 30, 2026

Phase III Phase III safety analysis Pooled safety data for obicetrapib in hypercholesterolemia

Market Reality Check

Price: $31.01 Vol: Volume 909,344 is close t...

normal vol

$31.01 Last Close

Volume Volume 909,344 is close to the 20-day average of 951,469 (relative volume 0.96). normal

Technical Shares trade below the 200-day MA at 29.92, after a -4.99% pre-news move.

Peers on Argus

Several biotech peers were also weak: RARE -3.17%, VKTX -3.84%, APLS -4.18%, whi...

Several biotech peers were also weak: RARE -3.17%, VKTX -3.84%, APLS -4.18%, while MLYS +4.11% and CRNX -0.7% showed mixed action, suggesting stock-specific plus broader biotech pressure.

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Inducement equity grants	Neutral	+3.0%	Options and RSUs granted to new hires under the 2024 Inducement Plan.
Feb 25	Investor conferences	Neutral	-2.8%	Management participation in multiple March investor conferences and webcasts.
Feb 18	Full-year 2025 earnings	Neutral	+1.5%	Full-year 2025 results plus updates on cash, trials, and regulatory filings.
Feb 06	Inducement option grants	Neutral	+2.0%	Option grants to non-executive hires with four-year vesting terms disclosed.
Feb 04	Biotech summit appearance	Neutral	-0.0%	Planned virtual fireside chat at a Guggenheim biotech investor summit.

Pattern Detected

Recent news has generally seen modest single‑digit price reactions, with both corporate updates and routine governance items moving the stock only slightly.

Recent Company History

Over the past few months, NewAmsterdam has focused on corporate visibility, governance items, and a major 2025 results update. The company reported $728.9M cash at 12/31/2025, ongoing Phase 3 programs, and regulatory submissions with decisions expected in 2H26. Routine inducement grants and conference appearances produced modest price moves, typically within a few percent. Today’s ACC presentation announcement fits this pattern of incremental clinical and scientific visibility rather than a discrete binary catalyst.

Market Pulse Summary

This announcement highlights upcoming ACC.26 presentations for obicetrapib, including BROADWAY kidne...

Analysis

This announcement highlights upcoming ACC.26 presentations for obicetrapib, including BROADWAY kidney function data, an integrated Phase III safety analysis, and work on LDL particle profiles. In the past months, NewAmsterdam has emphasized its cash position, ongoing Phase 3 trials, and regulatory submissions with decisions expected in 2H26. Investors may focus on how these scientific sessions frame obicetrapib’s safety and risk–benefit profile ahead of future topline and regulatory milestones.

Key Terms

low-density lipoprotein cholesterol, ldl-c, hypercholesterolemia, cetp inhibition, +2 more

6 terms

low-density lipoprotein cholesterol medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”)"

A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.

ldl-c medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”)"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

hypercholesterolemia medical

"low-dose therapy for hypercholesterolemia, at the at the American College"

Hypercholesterolemia is a medical condition where blood contains persistently high levels of cholesterol, a fatty substance that can build up in arteries and raise the risk of heart disease. For investors it matters because it drives demand for treatments, influences healthcare costs and insurance spending, and shapes the commercial outlook for drug makers, medical devices, and public health programs—like a steady customer base for therapies aimed at lowering cholesterol.

cetp inhibition medical

"CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients"

CETP inhibition is a drug mechanism that blocks a protein (cholesteryl ester transfer protein) that normally moves cholesterol between different blood carriers, so that protective “good” cholesterol levels rise while levels of harmful particles may fall or change. For investors, CETP inhibitors matter because they represent a pathway to treat heart disease risk; success or failure in clinical trials, safety signals, or regulatory decisions can strongly affect a drug developer’s value, much like a traffic controller changing the flow of vehicles alters congestion patterns.

phase iii medical

"Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

ldl particles medical

"discordantly high levels of Small/Medium LDL Particles Session Title"

LDL particles are microscopic carriers in the blood that transport cholesterol to cells; think of them as delivery trucks carrying fat. Having more or smaller, denser LDL particles increases the chance cholesterol will build up inside artery walls and raise the risk of heart disease. Investors watch LDL particle measurements because they influence demand for drugs, diagnostics and guidelines, affect clinical trial goals and regulatory decisions, and can move healthcare-related stocks.

AI-generated analysis. Not financial advice.

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana.

Presentation details are as follows:

Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial
Session Title: 1069: Next-Generation Lipid Treatment Options
Digital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT
Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma
Location: Moderated Poster Theater 06, Posters, Hall E

Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis   
Session Title: 1084: Evolving Non-Statin Therapies
Digital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT
Presenter: Adam Nelson, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E

Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles   
Session Title: 1180: Linking Lipid Metrics to CVD Risks
Digital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT
Presenter: Floriaan Schmidt, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E

About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What will NewAmsterdam Pharma (NAMS) present at ACC.26 on March 28, 2026?

NewAmsterdam will present a digital poster on obicetrapib preserving kidney function in BROADWAY. According to NewAmsterdam Pharma, the poster is scheduled for March 28, 2026 at 3:30 PM CDT in Moderated Poster Theater 06, Posters, Hall E.

When and where is the NewAmsterdam Pharma pooled Phase III safety analysis presentation at ACC.26?

The pooled Phase III safety analysis of obicetrapib will be presented on March 29, 2026 at 10:18 AM CDT. According to NewAmsterdam Pharma, the session is a digital poster in Moderated Poster Theater 05, Posters, Hall E.

Who will present NewAmsterdam Pharma's cardiovascular-events poster at ACC.26 and when is it scheduled?

Floriaan Schmidt, Ph.D. will present the cardiovascular-events poster on March 30, 2026 at 11:00 AM CDT. According to NewAmsterdam Pharma, the presentation is part of session 1180 in Moderated Poster Theater 05, Posters, Hall E.

Which trial is highlighted in NewAmsterdam Pharma's ACC.26 kidney-function poster for obicetrapib?

The kidney-function poster highlights results from the BROADWAY trial. According to NewAmsterdam Pharma, the presentation discusses CETP inhibition with obicetrapib and its preserved kidney function in high cardiovascular risk patients.

How can investors and clinicians view NewAmsterdam Pharma's ACC.26 presentations on obicetrapib?

Presentations are digital posters at ACC.26 on March 28-30, 2026 in New Orleans. According to NewAmsterdam Pharma, each poster will be shown in moderated poster theaters within the conference Posters Hall E with scheduled times listed by session.